SEP 19, 2017 10:30 AM PDT
WEBINAR: Structure and Function of Epigenetic Regulators in Human Disease
SPONSORED BY: Cell Signaling Technology
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
7 12 3186

Speakers:
  • Assistant Professor of Pediatric Oncology at the Dana-Farber Cancer Institute and Harvard Medical School and an Institute Member of the Broad Institute of MIT and Harvard
    Biography
      Cigall Kadoch is an Assistant Professor of Pediatric Oncology at the Dana-Farber Cancer Institute and Harvard Medical School and an Institute Member of the Broad Institute of MIT and Harvard. Dr. Kadoch studies chromatin regulation, with strong focus on the structure and function of the mammalian SWI/SNF or BAF family of chromatin remodeling complexes in human cancer. Her work has been centered in mechanistically interrogating rare, molecularly well-defined cancers, to understand the role these complexes play in promoting a wide range of more common cancer types.

      Kadoch completed her graduate studies at the Stanford University School of Medicine. Working alongside renowned developmental biologist Gerald Crabtree, she used a series of biochemical experiments to identify a novel set of protein components of the mSWI/SNF or BAF complex, which regulate chromatin structure. Upon these discoveries, Kadoch and her colleagues then linked mutations in the subunits of BAF complexes to more than one-fifth of human cancers-a number which continues to rise in light of increasingly completed sequencing efforts in human disease. In addition, she worked to uncover the oncogenic mechanism of BAF complex perturbation in a rare, aggressive soft-tissue sarcoma, known as synovial sarcoma. Kadoch is now developing new approaches to the structural and functional interrogation of chromatin regulators and developing therapeutic approaches for cancers driven by BAF mutations.

      Kadoch earned her undergraduate degree in Molecular and Cell Biology from the University of California, Berkeley, and her Ph.D. in Cancer Biology from the Stanford University School of Medicine. In 2014, shortly before becoming one of the youngest Assistant Professors ever appointed to the faculty of Harvard Medical School, she was named to Forbes Magazine's 30 Under 30 in Science & Healthcare, and in 2015, the MIT Technology Review Top Innovators Under 35. Among numerous awards, she is the recipient of the NIH Director's New Innovator Award, the American Cancer Society Research Scholar Award, and was recently named a Pew-Stewart Scholar in Cancer Research.
    • Director, Product Development at Cell Signaling Technology
      Biography
        Christopher Fry received his B.S. in Biology from Indiana University-Bloomington, where as an undergraduate he worked on a project utilizing mini-Tn5 transposon-mediated mutagenesis to identify novel genes regulating chemotactic responses and motility in the photosynthetic bacterium Rhodospirillum centenum. In 1999, Christopher earned his Ph.D. in Oncology from the University of Wisconsin-Madison, where he examined the mechanisms of E2F-mediated gene regulation during G1 and S phases of the mammalian cell cycle. Christopher then carried out his post-doctoral studies at the University of Massachusetts Medical School, where he studied mechanisms governing gene regulation, silencing, and chromatin dynamics during the cell cycle in the yeast Saccharomyces cerevisiae. Chris is currently an Associate Director of Product Development at Cell Signaling Technology, where he leads two teams, one that focuses on the development of antibodies against protein and non-protein targets involved in epigenetics, and the other that focuses the development of products for chromatin IP (ChIP).

      Abstract:

      DATE: September 19, 2017
      TIME: 10:30am PDT/ 1:30pm EDT/ 7:30pm CEST


      Part 1 – Cigall Kadoch, Ph.D. (30 min.)

      Exome- and genome-wide sequencing studies in human cancer have revealed a striking frequency of mutations in the genes encoding subunits of the mammalian SWI/SNF (BAF) family of ATP-dependent chromatin remodeling complexes. We recently determined these mutations to be broadly recurrent in over 20% of all cancers. I will present studies focused on the assembly and topological architecture of mammalian SWI/SNF complexes, cancer-specific complex subunit and associated protein factor composition, and novel approaches toward the identification of small molecule therapeutics for this class of human tumors.

      Part 2 – Chris Fry, Ph.D. (30 min.)

      The robustness and reliability of chromatin immunoprecipitation (ChIP) and ChIP-seq data is highly dependent on the quality of the antibodies and chromatin preparation used in the immunoprecipitation. I will provide an overview of the development and validation of new high quality recombinant rabbit monoclonal antibodies that show improved specificity, sensitivity, and reproducibility in ChIP and ChIP-seq assays. In addition, I will discuss important factors to consider for optimizing different types of target proteins, including histones, transcription factors, and transcription cofactors.

       

      Learning Objectives:

      • The assembly and biological architecture of mammalian SWI/SNF complexes..
      • The role of cancer-specific SWI/SNF complex mutations (present in 20% of cancers) in driving oncogenicity.
      • Novel approaches toward the identification of small molecule therapeutics for this class of human tumors.
      • Development and validation of new high quality recombinant monoclonal antibodies for ChIP and ChIP-seq.
      • Important factors to consider for optimizing different types of proteins – including histones, transcription factors, and cofactors – for ChIP.
         

       


      Show Resources
      Loading Comments...